

**NEWS RELEASE**

**BIOSENSORS ANNOUNCES INCREASED PRODUCT REVENUES  
FOR THIRD QUARTER AND FIRST NINE MONTHS OF FISCAL 2007**

**Singapore, 8 February 2007** - Biosensors International Group, Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP) today announced financial results for the third fiscal quarter (“3Q FY07”) and the nine months ending December 31, 2006. Product revenues were US\$8.3 million for 3Q FY07 compared to US\$7.9 million for the same period in the prior year, an increase of 4%. For the nine months ending December 31, 2006, product revenues were US\$24.4 million compared to US\$20.8 million for the prior year period, an increase of 17%.

In 3Q FY07, revenue from drug-eluting stents was US\$2.6 million compared to US\$3.4 million in the prior year’s quarter. The decline in drug-eluting stent sales in the quarter was attributable to reduced usage in certain European countries amid concerns that first generation drug-eluting stents may put patients at higher risk of blood clots than conventional bare-metal stents, as reported at the World Cardiology Congress (“WCC”) held in Barcelona in September 2006. For the nine-month period ending December 31, 2006, revenue from drug-eluting stents was US\$8.8 million, approximately 52% higher than US\$5.8 million for the prior year’s period.

Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors said, “Over the first nine months of this fiscal year, we saw strong growth in sales of our drug-eluting stent compared to the same period in the last fiscal year. Unfortunately, the issue of clotting associated with current generation drug-eluting stents which use durable polymers created a concern among cardiologists and affected the sales opportunities for all drug-eluting stents during the period. We anticipate that the drug-eluting stent market will return to a normal growth pattern, although we expect the market will demand better safety profiles from drug-eluting stents in the future. In scientific meetings following the WCC in Barcelona, drug-eluting stents that have a polymer that disappears over time following implantation gained wider attention and were actively discussed at the Transcatheter Cardiovascular Therapeutics (“TCT”) conference in Washington DC in October 2006 and recently at the Singapore LIVE convention in January this year.”

Mr Lu added, “Our BioMatrix® drug-eluting stent system has always been well-positioned in this environment as its biodegradable polymer and drug delivery system specifically address the current safety concerns of blood clot formation. Better yet, at TCT 2006, we also introduced our newest generation drug-eluting stent, our BioMatrix®-Freedom™ stent that does not use a polymer. We are pleased that our drug-eluting stent technology has been widely regarded by cardiologists as the frontier technology. We will continue to invest in our technology development to enable us to introduce new, improved drug-eluting stent platforms. At the same time we will also beef up our resources, particularly the sales and marketing functions to support the pending launch of BioMatrix.”

Research and development (“R&D”) expenses which include costs for new product development and testing, clinical trials, patent registration and regulatory approvals were US\$5.6 million in 3Q FY07 compared to US\$5.4 million in the prior year’s corresponding period. Sales and marketing expenses were US\$3.1 million in 3Q FY07 compared to US\$2.1 million in the prior year’s corresponding quarter. The increases were due mainly to expenses incurred for increased participation in trade show activities and brand-building activities as well as higher payroll expenses associated with actions to further enhance the sales and marketing functions in preparation for the BioMatrix launch. General and administrative expenses were US\$5.3 million in 3Q FY07 compared to US\$3.9 million in the prior year’s corresponding quarter. The increase was primarily due to share-based option expenses as well as amortization of intangible assets.

For the quarter under review, the Group reported a net loss of US\$10.4 million or 1.14 US cent loss per basic and diluted share, compared to a net loss of US\$7.5 million or 0.86 US cent loss per basic and diluted share for the prior year’s corresponding period.

The Company also announced that it is in the process of converting to the US Generally Accepted Accounting Principles (“US GAAP”) for its financial reporting and expects to complete the conversion from its existing International Financial Reporting Standards (IFRS) in the near future.

Commenting on the conversion of accounting practices, Mr Lu said, “Most stent companies are US-based and adopting US GAAP is a logical step for us since this will enable our global investors to have direct financial performance comparisons against our competitors.”

**MORE-MORE-MORE**

##End of Release##

**Media Contact**

***Biosensors International Group***

Ms Tina Lim, Executive, Corporate Communications

Tel: (65) 6213 5712

Email: [media@biosensors.com](mailto:media@biosensors.com)

**Media Relations / Investor Relations Firm**

**United States**

***Allen & Caron Inc.***

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: [matt@allencaron.com](mailto:matt@allencaron.com)

**About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenotic drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*<sup>®</sup>, *Axxion*<sup>™</sup>, and *BioMatrix*<sup>®</sup> *Freedom*<sup>™</sup>, a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

**Forward-Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*